Clinical Evaluation Report Requirements in the UK

1. Key takeaways

The UK has not adopted the dedicated clinical evaluation chapter structure of EU MDR Annex XIV. Instead it retains the instruction-era architecture: clinical evaluation is required as part of the evidence of conformity with the relevant essential requirements, through reg 8, reg 9 and the annexes those provisions incorporate. Since 16 June 2025, when Part 4A came into force, the Clinical Evaluation Report (CER) must also form a closed loop with post-market surveillance data: PMS data are an input to the CER, and the CER’s conclusions must be updated as PMS data evolve. In practical terms, a UK clinical evaluation is at once more familiar and more dynamic than its EU MDR counterpart. Familiar, because the underlying evidential categories, literature, equivalence and clinical investigations, are the ones manufacturers have used for years. Dynamic, because the report now sits inside a surveillance system with defined reporting cycles and defined response deadlines. The sections below set out the legal provisions behind both halves of that picture, the points where UK practice diverges from EU practice, and the operational habits that keep the CER current rather than archival. For manufacturers maintaining parallel EU and UK files, this dual character matters: the EU dossier tends to grow through formal assessments, while the UK CER grows through scheduled surveillance reviews, and keeping the two rhythms distinct avoids confusion about which document changed and why.

2. Legal basis

• UK MDR 2002 (SI 2002/618, as amended): reg 8 (the relevant essential requirements), reg 9 (assessment of conformity), reg 16 (the procedure for clinical investigations of general devices), reg 29 (the procedure for clinical investigations of active implantable devices), and Schedule 2A.
• SI 2024/1368 (made 16 December 2024, in force 16 June 2025): Part 4A, including reg 44ZE (the PMS system), reg 44ZF (the PMS plan), reg 44ZL (the PMSR) and reg 44ZM (the PSUR).
• The Medicines and Medical Devices Act 2021: the enabling act under which SI 2023/627 was made (sections 15, 16, 17 and 43).

3. Expert insights

Insight one: the evidential weight required of a UK CER differs from the EU approach. Because the UK relevant essential requirements retain the directives’ wording, the acceptable routes for clinical evidence, literature, equivalent devices and clinical investigations, remain more flexible in practice than under EU MDR. That flexibility, however, does not mean evidence quality can be lowered. The MHRA can request supplementary technical documentation during registration checks, and a thin or dated CER is exactly the kind of gap such a request exposes. The correct reading is procedural, not substantive: the UK gives manufacturers more room to choose how they demonstrate conformity, while holding them to the same obligation to actually demonstrate it. A practical discipline is to record, in the file itself, which route supports each clinical claim, because an unstated route is the first thing a reviewer asks about.

Insight two: Part 4A turns the CER from a static document into a dynamic one. Reg 44ZF requires a PMS plan to be established and maintained, and reg 44ZE requires the data generated by the PMS system to be used to update the technical documentation. If the CER is disconnected from PMS, it cannot be updated within the 3 working day window that applies when the MHRA requests documents under reg 44ZR. The operational implication is that the CER’s data inputs, its search strings, its complaint feeds and its update triggers, must already be wired into the PMS process before any request arrives, because three working days is not enough time to build those connections from scratch. GRZAN therefore encourages manufacturers to rehearse the scenario annually, asking how the CER would actually be updated if a request arrived mid-cycle.

Insight three: clinical investigations and post-market activity are two separate procedures. Clinical investigations conducted in the UK proceed under reg 16 for general devices and reg 29 for active implantable devices, and must be accompanied by ethics committee review. They are not a substitute for the CER; they are one of its evidential sources. A clinical investigation generates data that enter the CER, while the CER’s conclusions continue to be tested by post-market data long after the investigation closes. Treating the investigation report as the end of the clinical story misreads how the two regimes connect. Keeping the two streams separate in the documentation, investigation records under their own provisions and evaluation conclusions in the CER, keeps the evidence trail clean for both audiences.

4. Practical recommendations

GRZAN recommends binding the CER’s update triggers to the PMSR/PSUR cycles: for Class I devices, review the CER alongside the 3-yearly PMSR; for Class IIa, alongside the 2-yearly PSUR; and for Class IIb and Class III, alongside the annual PSUR. Aligning the two rhythms means every surveillance report naturally opens a question about whether the clinical conclusions still hold, and the answer gets recorded while the underlying data are fresh. Within the CER itself, GRZAN suggests dedicating a distinct section to PMS data inputs, stating which data sources were used in the current period and what changed in the conclusions as a result. That single section, kept current, is what demonstrates the closed loop between surveillance and evaluation when the MHRA or an auditor examines the file, and it costs far less to maintain than to reconstruct. For legacy devices with no recent surveillance activity, GRZAN suggests recording a reasoned negative review rather than leaving the period blank, since an explicit conclusion of no change is itself evidence of a functioning loop.

5. Verification checklist

• □ The CER is structured against the UK relevant essential requirements
• □ A feedback mechanism exists between the CER and PMS data
• □ The CER update cycle is bound to the PMSR/PSUR cycles
• □ Where clinical investigations are run, the reg 16 / reg 29 procedures have been followed
• □ The CER can be produced within 3 working days of an MHRA request

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers entering the UK market with the preparation and maintenance of registration documentation and conformity documentation. Our services for the UK market include:

• UK Responsible Person (UKRP) appointment and authorisation letter support
• Full MHRA registration (DORS) filing and account lifecycle management
• Device classification, GMDN code selection and annual registration fee calculation
• Great Britain and Northern Ireland dual-pathway design and UK(NI) solutions
• Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance reporting
• Serious incident and field safety corrective action (FSCA) emergency response
• UK regulatory change monitoring and compliance gap assessment

For tailored support with UK clinical evaluation and post-market surveillance documentation, contact GRZAN at info@grzanglobal.com.